175 related articles for article (PubMed ID: 32697338)
21. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
[No Abstract] [Full Text] [Related]
22. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
23. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Palandri F; Catani L; Bonifacio M; Benevolo G; Heidel F; Palumbo GA; Crugnola M; Abruzzese E; Bartoletti D; Polverelli N; Bergamaschi M; Tiribelli M; Iurlo A; Breccia M; Cavazzini F; Tieghi A; Binotto G; Isidori A; Martino B; D'Adda M; Bosi C; Sabattini E; Vitolo U; Aversa F; Ibatici A; Lemoli RM; Sgherza N; Cuneo A; Martinelli G; Semenzato G; Cavo M; Vianelli N; Sapienza MR; Latagliata R
Br J Haematol; 2018 Oct; 183(1):35-46. PubMed ID: 30010187
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
26. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Breccia M; Luciano L; Pugliese N; Rossi E; Tiribelli M; Scalzulli E; Bonifacio M; Martino B; Latagliata R; Benevolo G; Caocci G; Binotto G; Martinelli V; Cavo M; Pane F; De Stefano V; Foà R; Palandri F
Ann Hematol; 2019 Aug; 98(8):1933-1936. PubMed ID: 31201513
[TBL] [Abstract][Full Text] [Related]
28. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
29. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
30. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis.
Mascarenhas J; Hoffman R
Blood; 2013 Jun; 121(24):4832-7. PubMed ID: 23570800
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
Palandri F; Tiribelli M; Benevolo G; Tieghi A; Cavazzini F; Breccia M; Bergamaschi M; Sgherza N; Polverelli N; Crugnola M; Isidori A; Binotto G; Heidel FH; Buccisano F; Martino B; Latagliata R; Spinsanti M; Kallenberg L; Palumbo GA; Abruzzese E; Scaffidi L; Cuneo A; Cavo M; Vianelli N; Bonifacio M
Hematol Oncol; 2018 Feb; 36(1):285-290. PubMed ID: 28512865
[TBL] [Abstract][Full Text] [Related]
35. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups.
Murata M; Takenaka K; Uchida N; Ozawa Y; Ohashi K; Kim SW; Ikegame K; Kanda Y; Kobayashi H; Ishikawa J; Ago H; Hirokawa M; Fukuda T; Atsuta Y; Kondo T
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1536-1543. PubMed ID: 30826464
[TBL] [Abstract][Full Text] [Related]
37. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Mazza P; Specchia G; Di Renzo N; Cascavilla N; Tarantini G; Capalbo SF; Urbano T; Albano F; Giovannni R; Falcone AP; Santeramo MT; Spinosa G; Pisconti S
Leuk Lymphoma; 2017 Jan; 58(1):138-144. PubMed ID: 27263544
[TBL] [Abstract][Full Text] [Related]
39. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P; Griesshammer M; Guglielmelli P; Bouard C; Paley C; Tiwari R; Vannucchi AM
Hematol Oncol; 2021 Oct; 39(4):558-566. PubMed ID: 34224180
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Masarova L; Verstovsek S; Hidalgo-Lopez JE; Pemmaraju N; Bose P; Estrov Z; Jabbour EJ; Ravandi-Kashani F; Takahashi K; Cortes JE; Ning J; Ohanian M; Alvarado Y; Zhou L; Pierce S; Gergis R; Patel KP; Luthra R; Kadia TM; DiNardo CD; Borthakur G; Bhalla K; Garcia-Manero G; Bueso-Ramos CE; Kantarjian HM; Daver N
Blood; 2018 Oct; 132(16):1664-1674. PubMed ID: 30185431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
